Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study

EP Europace Journal

29 June 2026
Organised by: Logo
ESC Journals ARRHYTHMIAS AND DEVICE THERAPY Arrhythmias, General Atrial Fibrillation (AF) VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Abstract

AbstractAims

Atrial fibrillation (AF) is highly prevalent among cardiac amyloidosis (CA) patients and contributes significantly to their morbidity and mortality. Evidence regarding AF ablation efficacy and safety in CA patients remains limited. The aim of our study is to evaluate baseline characteristics, clinical course and outcomes of AF ablation in a series of patients with transthyretin (ATTR) or light-chain (AL) CA from a multicentre international registry.

Methods and results

Patients with CA who underwent AF ablation were included. Co-primary endpoints were: (i) atrial arrhythmia (AA) recurrence; (ii) a composite endpoint of all-cause mortality and heart failure hospitalization (HFH). 109 patients (mean age 72.4 ± 7.4 years, females 17.4%, persistent AF 64.2%, ATTR 78%, AL 22%) were included. Radiofrequency, cryo-balloon and pulsed-field ablation were performed in 67%, 15% and 18% of patients, respectively; 49.5% received pulmonary vein isolation plus additional ablations. Low voltage zones were documented in 34 out of 44 patients undergoing electro-anatomical mapping (77.3%). During a median follow-up of 22.7 months, 63 patients (58.3%) experienced AA recurrence (32.4% persistent AF recurrence), with no significant differences between CA subtypes (ATTR 59.5% vs. AL 54.2%, log-rank P = 0.55). The composite endpoint of HFH and all-cause death occurred in 27 patients (25%). Recurrence of persistent AF was associated with three-fold higher risk (OR 2.9, P = 0.02) of the composite endpoint.

Conclusion

CA patients undergoing AF ablation present high prevalence of persistent AF. Freedom from AA after AF ablation is achieved in 42% of patients after a two-year follow-up. Patients with persistent AF recurrence have a three-fold higher risk of HFH and death.

Contributors

Daniele Faccenda
Daniele Faccenda

Author

Istituto Cardiocentro Ticino Lugan , Switzerland

Marco Bergonti
Marco Bergonti

Author

Cardiocentro Ticino Institute Lugano , Switzerland

Tom De Potter
Tom De Potter

Author

Cardiovascular Research Center Aalst Aalst , Belgium

Johan Saenen
Johan Saenen

Author

University Hospital Antwerp Edegem , Belgium

Michela Casella
Michela Casella

Author

Marche Polytechnic University of Ancona Ancona , Italy

Jacopo Costantino
Jacopo Costantino

Author

Sapienza University of Rome Rome , Italy

Daniel Scherr
Daniel Scherr

Author

Medical University of Graz Graz , Austria

Patrizio Mazzone
Patrizio Mazzone

Author

ASST Great Metropolitan Niguarda Milan , Italy

Avi Sabbag
Avi Sabbag

Author

Chaim Sheba Medical Center Ramat Gan , Israel

Matteo Anselmino
Matteo Anselmino

Author

Hospital Citta Della Salute e della Scienza di Torino Turin , Italy

Matteo Bertini
Matteo Bertini

Author

University Hospital of Ferrara Ferrara , Italy

Christian-Hendrik Heeger
Christian-Hendrik Heeger

Author

Asklepios Clinic Altona Hamburg , Germany

Claudio Tondo
Claudio Tondo

Author

Centro Cardiologico Monzino-IRCCS Milano , Italy

Elena Arbelo
Elena Arbelo

Author

Hospital Clinic, University of Barcelona Barcelona , Spain

Olivier Van Leuven
Olivier Van Leuven

Author

Antwerp University Hospital Edegem , Belgium

Tardu Özkartal
Tardu Özkartal

Author

Cardiocentro Ticino Institute Lugano , Switzerland

Cristina Balla
Cristina Balla

Author

Sant Anna Hospital Ferrara , Italy

Marco Schiavone
Marco Schiavone

Author

Monzino Cardiology Centre Milan , Italy

Cinzia Monaco
Cinzia Monaco

Author

CHU Bordeaux Bordeaux , France

Giulio Conte
Giulio Conte

Author

Cardiocentro Ticino Institute Lugano , Switzerland